Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study.
<br />Dr. Joseph Tabernero, MD, discusses the phase 3 keynote-062 study.<br /><br />Background: KEYNOTE062 (NCT02494583) was a randomized, active controlled study of 1L P or P+C vs C in pts with PD-L1 combined po...
Author: Annual-Meeting
Added: 06/06/2019
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
More News: Adenocarcinoma | Cancer & Oncology | Chemotherapy | Gastric (Stomach) Cancer | Gastroenterology | Study